Concetta Torromeo

Concetta Torromeo

Auto-generated profile, based on publicly available information

Concetta Torromeo

Sapienza University

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
CSClaudia Stefanutti
Claudia Stefanutti
UJUlrich Julius
Ulrich Julius
GWGerald F. Watts
Gerald F. Watts
MHMariko Harada-Shiba
Mariko Harada-Shiba
MCMaria Cossu
Maria Cossu
DNDe Luca N
De Luca N
Despite advances in pharmacotherapy of lipid disorders, many dyslipidemic patients do not attain sufficient lipid lowering to mitigate risk of atherosclerotic cardiovascular disease. Several classes of novel lipid-lowering agents are being evaluated to reduce atherosclerotic cardiovascular disease risk. Lipoprotein apheresis (LA) is effective in acutely lowering the plasma concentrations of atherogenic lipoproteins including low-density lipoprotein cholesterol and lipoprotein(a), and novel lipid-lowering drugs may dampen the lipid rebound effect of LA, with the possibility that LA frequency may be decreased, in some cases even be discontinued. This document builds on current American Society for Apheresis guidelines and, for the first time, makes recommendations from summarized data of the emerging lipid-lowering drug classes (inhibitors of proprotein convertase subtilisin/kexin type 9 or microsomal triglyceride transfer protein, high-density lipoprotein mimetic), including the available evidence on combination therapy with LA with respect to the management of patients with dyslipidemia. Recommendations for different indications are given based on the latest evidence. However, except for lomitapide in homozygous familial hypercholesterolemia and alirocumab/evolocumab in heterozygous familial hypercholesterolemia subjects, limited data are available on the effectiveness and safety of combination therapy. More studies on combining LA with novel lipid-lowering drugs are needed. Novel lipid-lowering agents have potential to improve the performance of LA, but more evidence is needed. The Multidisciplinary International Group for Hemapheresis TherapY and Metabolic DIsturbances Contrast scientific society aims to establish an international registry of clinical experience on LA combination therapy to expand the evidence on this treatment in individuals at high cardiovascular disease risk.

1 March 2013 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
Manuela MerliManuela Merli
Manuela Merli
ACAngela Calicchia
Angela Calicchia
ARAlessandra Ruffa
Alessandra Ruffa
PPPierpaolo Pellicori
Pierpaolo Pellicori
OROliviero Riggio
Oliviero Riggio
CTConcetta Torromeo
Concetta Torromeo

16 June 2016 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
FBFrancesco Barillà
Francesco Barillà
GPGiuseppe Pannarale
Giuseppe Pannarale
CTConcetta Torromeo
Concetta Torromeo
VPVincenzo Paravati
Vincenzo Paravati
MAMaria Cristina Acconcia
Maria Cristina Acconcia
CGCarlo Gaudio
Carlo Gaudio

19 November 2016 in Liver International
Verified
Journal Article
Closed access
PDF file
Manuela MerliManuela Merli
Manuela Merli
CTConcetta Torromeo
Concetta Torromeo
MGMichela Giusto
Michela Giusto
GIGianna Iacovone
Gianna Iacovone
OROliviero Riggio
Oliviero Riggio
PPPaolo E. Puddu
Paolo E. Puddu

1 October 2011 in Progress in Biophysics and Molecular Biology
Verified
Journal Article
Closed access
AEA. Evangelista
A. Evangelista
PNP. Nardinocchi
P. Nardinocchi
Paolo Emilio PudduPaolo Emilio Puddu
Paolo Emilio Puddu
LTLuciano Teresi
Luciano Teresi
CTC. Torromeo
C. Torromeo
VVV. Varano
V. Varano

1 June 1989 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
MLM. Lazzarino
M. Lazzarino
AVA. Vitale
A. Vitale
EME. Morra
E. Morra
AGA. Gagliardi
A. Gagliardi
PBPaolo Bernasconi
Paolo Bernasconi
FMF. Mandelli
F. Mandelli